Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
Adela develops blood-based diagnostic tests that analyze cell-free DNA using whole methylome analysis to detect and monitor cancer. It serves clinicians and biopharma partners with applications including early multi-cancer detection, minimal residual disease detection, and immunotherapy response monitoring.
3 investors
3 investors
AdrenoMed AG is a clinical-stage biopharmaceutical company developing Enibarcimab (formerly Adrecizumab), a first-in-class antibody targeting the peptide Adrenomedullin to restore vascular integrity in critically ill patients, with septic shock as its lead indication. It applies a biomarker-guided precision medicine approach to identify patients most likely to benefit and is based in the Berlin area of Germany.
3 investors
Advanced Catheter Therapies develops the Pressana Occlusion Perfusion Catheter, a medical device for targeted endovascular delivery of therapeutic agents to treat peripheral arterial disease and prevent limb amputation. The device is FDA-cleared for below-the-knee use and enables localized infusion of various physician-prescribed medications to prevent restenosis after vessel modification procedures.
3 investors
Advemto maps complex cell function to genetic sequences at scale without requiring new laboratory instruments. The platform targets therapeutic development and TechBio companies seeking to accelerate preclinical validation of next-generation therapeutics.
3 investors
Aegle Therapeutics develops therapies using extracellular vesicles (EVs) isolated from mesenchymal stem cells to deliver therapeutic biomolecules to diseased and damaged cells. Its lead product, AGLE-102, targets dystrophic epidermolysis bullosa, a rare pediatric skin-blistering disease, with potential applications across dermatology, immunology, and protein-deficiency disorders.
3 investors
Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology. The company has been acquired by GSK.
3 investors
AgGene develops crop traits to improve resilience, harvest stability, and seed value, with a primary focus on canola addressing challenges like environmental stress and pod shatter, plus pulse programs for improved protein and ingredient quality. The company serves Canadian agriculture and was founded by scientists, farmers, and industry experts.
3 investors
AgriTX develops AGRITX-F65, a proprietary blend of pre/probiotics, vitamins, amino acids, and minerals applied to the eggshell microbiome of fertilized avian eggs to improve hatch rates, chick quality, and livability. The product targets poultry producers and broiler breeder operations in the agricultural biotech space.
3 investors
Ahammune develops small-molecule therapeutics for chronic skin diseases, with a lead program targeting vitiligo by restoring deregulated cellular pathways in the skin. The company focuses on dermatology drug discovery.
3 investors
AIVIVO develops drug discovery solutions at the organism level, focusing on accelerating pharmaceutical development processes.
3 investors
Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.
3 investors
Alafair Biosciences develops naturally-derived hydrogel products for soft-tissue protection during surgery, using a hyaluronic acid and alginate technology to create a protective gliding surface that prevents postoperative tissue tethering and scarring. Its products, sold as a hydrogel sheet and a flowable syringe-deliverable gel, are used by surgeons to protect tendons and peripheral nerves during soft-tissue procedures.
3 investors
Alamar Biosciences develops NULISA, an ultra-high-sensitivity, high-specificity technology for analyzing hundreds of protein biomarkers from small biofluid samples, building on the team's prior spatial genomics work (RNAscope). The company serves proteomics research and clinical drug development applications.
3 investors
Alebund Pharmaceuticals develops innovative treatments for kidney diseases, with a pipeline covering chronic kidney conditions such as diabetic nephropathy, IgA nephropathy, FSGS, and ADPKD, as well as end-stage renal disease complications like hyperphosphatemia and anemia. The company operates across drug research, manufacturing, and commercialization for kidney disease patients globally.
3 investors
Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer. The company is advancing Enolen, a drug-eluting implant designed to deliver enzalutamide directly to the prostate with fewer systemic side effects than existing treatments.
3 investors
Alesta Therapeutics is a biotech company developing oral small molecule therapies for rare diseases with limited treatment options. It focuses on targeted drugs suitable for all age groups, emphasizing safety, efficacy, and accessibility.
3 investors
Alexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.
3 investors
Alida Biosciences develops EpiPlex, a platform for detecting RNA modifications (m6A, inosine, and pseudouridine) through both turnkey profiling services and in-lab kits, with EpiScout machine-learning software that converts sequencing data into analysis results. It serves researchers in epitranscriptomics and supports real-world sample types such as FFPE, liquid biopsy, and RNA-limited inputs.
3 investors
Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions. The company focuses on gene therapies and other advanced treatment modalities for ophthalmology.
3 investors
Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).
3 investors
A venture studio embedded within Alloy Therapeutics that partners with academics, entrepreneurs, pharma companies, and VCs to create and develop early-stage drug discovery companies. It gives its portfolio companies access to Alloy's discovery technologies and enabling services, and support in strategy, legal, R&D funding, and partnerships to reach Series A financing.
3 investors
Allozymes develops custom enzymes using high-throughput experimentation combined with AI-guided design for enzyme engineering and biocatalysis. It applies these engineered enzymes to industrial and scientific applications.
3 investors
Alpine Bio develops high-purity protein ingredients and bioactives derived from plants using molecular farming and advanced purification methods. The company targets food and beverage formulators seeking soluble, neutral-flavored, clean-label functional ingredients.
3 investors